Targeted cell-to-cell mRNA delivery of therapeutic circuits
Targeted cell-to-cell mRNA delivery of therapeutic circuits
批准号:
10827328
负责人:
Victoria Rose Tobin
金额:
$5.27万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-01 至 2028-08-31
关键词:
AddressBiological AssayBypassCapsid ProteinsCaspaseCell Death InductionCell LineCell ReprogrammingCell TherapyCellsDiseaseERBB2 geneElementsEngineeringEnsureGene MutationGenesGoalsHomeHumanImmuneImmunosuppressionIn VitroK-562LogicMalignant NeoplasmsMeasuresMessenger RNAMethodsMusNon-Insulin-Dependent Diabetes MellitusPathogenicityPatientsPopulationProductionProtein EngineeringProteinsRNARNA-Binding ProteinsRegional DiseaseSpecificitySurface AntigensSystemT-LymphocyteTestingTherapeuticTherapeutic AgentsTissuesTransfectionViralWorkburden of illnesscancer cellcell killingcell typeclinically relevantdelivery vehicledisease-causing mutationengineered T cellsepidermal growth factor receptor VIIIgenome editingimmunoengineeringin vivoin vivo ModelmRNA ExportmRNA deliverymouse modelneoplastic cellnovelparticleprotein expressionreceptorsensortherapeutic proteintumor
中文摘要
项目总结
英文摘要
Project Summary
mRNA holds great therapeutic potential as an agent to induce expression of proteins in cells. Precise delivery of
mRNA to diseased cell types could have numerous applications, from correcting pathogenic mutations by gene
editing to inducing killing in diseased cell types to cell state reprogramming. Despite this potential, it remains
challenging to deliver mRNA to specific subsets of cells. A general method to safely deliver mRNA cargo to
target cell types within a patient’s body would unlock the full therapeutic potential of mRNA. Living cells are ideal
delivery vehicles because they can be programmed to use sensing and logic to specifically deliver mRNA to
target cell populations.
Towards this goal, our lab has recently developed delivery cells capable of exporting mRNA in synthetic export
vehicles (synEVs). These particles can transfer mRNA cargo to receiver cells, where it is expressed. In this
proposal, we aim to create, optimize, and integrate elements to generate an ideal cell-based mRNA delivery
platform. In Aim 1, we will engineer primary human T cells, a clinically relevant cell type, as delivery cells. In Aim
2, we will develop strategies to control targeting specificity by engineering conditional sending and pseudotyping.
In Aim 3, we will demonstrate cell-cell delivery and functionality of mRNA in vivo by delivering a circuit that
induces cell death to tumor cells, which should bypass the immunosuppression that limits traditional immune
cell-based therapies.
Together, this work will expand our capabilities in cell-cell mRNA delivery and enable a novel, cell-based tumor
killing strategy that circumvents immunosuppression. Further, while we focus on applications related to cancer
in this proposal, this work will establish a platform with broad utility across biomedicine, including for in vivo cell
reprogramming and genome editing.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金